|
1
|
Trakatelli M, Ulrich C, del Marmol V,
Euvrard S, Stockfleth E and Abeni D: Epidemiology of nonmelanoma
skin cancer (NMSC) in Europe: accurate and comparable data are
needed for effective public health monitoring and interventions. Br
J Dermatol. 156(Suppl 3): 1–7. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim RH and Armstrong AW: Nonmelanoma skin
cancer. Dermatol Clin. 30:125–139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rogers HW, Weinstock MA, Harris AR, et al:
Incidence estimate of nonmelanoma skin cancer in the United States,
2006. Arch Dermatol. 146:283–287. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baron JA, Cole BF, Sandler RS, et al: A
randomized trial of aspirin to prevent colorectal adenomas. N Engl
J Med. 348:891–899. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gravitz L: Chemoprevention: First line of
defence. Nature. 471:S5–S7. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Elmets CA, Viner JL, Pentland AP, et al:
Chemoprevention of nonmelanoma skin cancer with celecoxib: a
randomized, double-blind, placebo-controlled trial. J Natl Cancer
Inst. 102:1835–1844. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cuzick J, Otto F, Baron JA, et al: Aspirin
and non-steroidal anti-inflammatory drugs for cancer prevention: an
international consensus statement. Lancet Oncol. 10:501–507. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nie T, Wong CC, Alston N, Aro P,
Constantinides PP and Rigas B: Phospho-ibuprofen (MDC-917)
incorporated in nanocarriers: anticancer activity in vitro and in
vivo. Br J Pharmacol. Dec 5–2011, (Epub ahead of print).
|
|
9
|
Wong CC, Cheng KW, Xie G, et al:
Carboxylesterases 1 and 2 hydrolyze phospho-NSAIDs: relevance to
their pharmacological activity. J Pharmacol Exp Ther. 340:422–432.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mattheolabakis G, Nie T, Constantinides PP
and Rigas B: Sterically stabilized liposomes incorporating the
novel anti-cancer agent phospho-ibuprofen (MDC-917): preparation,
characterization, and in vitro/in vivo evaluation. Pharm Res. Nov
10–2011, (Epub ahead of print).
|
|
11
|
Huang L, Mackenzie GG, Sun Y, et al:
Chemotherapeutic properties of phospho-nonsteroidal
anti-inflammatory drugs, a new class of anticancer compounds.
Cancer Res. 71:7617–7627. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie G, Nie T, Mackenzie G, et al: The
metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and
the effect of difluoromethylornithine. Br J Pharmacol.
165:2152–2166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun Y, Huang L, Mackenzie GG and Rigas B:
Oxidative stress mediates through apoptosis the anticancer effect
of phosphononsteroidal anti-inflammatory drugs: implications for
the role of oxidative stress in the action of anticancer agents. J
Pharmacol Exp Ther. 338:775–783. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mackenzie GG, Ouyang N, Xie G, et al:
Phospho-sulindac (OXT-328) combined with difluoromethylornithine
prevents colon cancer in mice. Cancer Prev Res (Phila).
4:1052–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xie G, Sun Y, Nie T, et al:
Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer:
efficacy, metabolism, and pharmacokinetics in mouse models. J
Pharmacol Exp Ther. 337:876–886. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang L, Mackenzie G, Ouyang N, et al: The
novel phospho-non-steroidal anti-inflammatory drugs, OXT-328,
MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br
J Pharmacol. 162:1521–1533. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang L, Zhu C, Sun Y, et al:
Phospho-sulindac (OXT-922) inhibits the growth of human colon
cancer cell lines: a redox/polyamine-dependent effect.
Carcinogenesis. 31:1982–1990. 2010. View Article : Google Scholar
|
|
18
|
Mackenzie GG, Sun Y, Huang L, et al:
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe
and effective in colon cancer prevention in mice. Gastroenterology.
139:1320–1332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kozoni V, Tsioulias G, Shiff S and Rigas
B: The effect of lithocholic acid on proliferation and apoptosis
during the early stages of colon carcinogenesis: differential
effect on apoptosis in the presence of a colon carcinogen.
Carcinogenesis. 21:999–1005. 2000. View Article : Google Scholar
|
|
20
|
Ahmed S, Imai T, Yoshigae Y and Otagiri M:
Stereospecific activity and nature of metabolizing esterases for
propranolol prodrug in hairless mouse skin, liver and plasma. Life
Sci. 61:1879–1887. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Akarsu S, Aktan S, Atahan A, Koc P and
Ozkan S: Comparison of topical 3% diclofenac sodium gel and 5%
imiquimod cream for the treatment of actinic keratoses. Clin Exp
Dermatol. 36:479–484. 2011.
|
|
22
|
McCarberg BH and Argoff CE: Topical
diclofenac epolamine patch 1.3% for treatment of acute pain caused
by soft tissue injury. Int J Clin Pract. 64:1546–1553
|
|
23
|
Fuller P and Roth S: Diclofenac sodium
topical solution with dimethyl sulfoxide, a viable alternative to
oral nonsteroidal anti-inflammatories in osteoarthritis: review of
current evidence. J Multidiscip Healthc. 4:223–231. 2011.
View Article : Google Scholar : PubMed/NCBI
|
